Sysmex (SSMX.Y) Stock Overview
Engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for SSMX.Y from our risk checks.
SSMX.Y Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Sysmex Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥12.48 |
| 52 Week High | JP¥14.20 |
| 52 Week Low | JP¥8.01 |
| Beta | 0.69 |
| 1 Month Change | 31.78% |
| 3 Month Change | 52.57% |
| 1 Year Change | -9.37% |
| 3 Year Change | -31.18% |
| 5 Year Change | -65.50% |
| Change since IPO | 120.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| SSMX.Y | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 24.0% | 1.6% | 2.2% |
| 1Y | -9.4% | -11.1% | 20.9% |
Return vs Industry: SSMX.Y exceeded the US Medical Equipment industry which returned -12.8% over the past year.
Return vs Market: SSMX.Y underperformed the US Market which returned 20.9% over the past year.
Price Volatility
| SSMX.Y volatility | |
|---|---|
| SSMX.Y Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SSMX.Y has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SSMX.Y's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1968 | 10,861 | Hisashi Ietsugu | www.sysmex.co.jp |
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers hematology, a major test routinely included in blood tests; Flow Cytometry (FCM) analyzes cell properties by irradiating individual cells with a laser and measuring the intensity of light scattering and fluorescence; urinalysis test checks for the presence of glucose, proteins, and blood in urine; clinical chemistry; hemostasis; immunochemistry; cancer gene testing; and antimicrobial susceptibility testing. The company also provides Caresphere, an ICT solution, which integrates and analyzes real time various data managed through testing instruments and clinical testing information systems, and supports the efficient operation of clinical laboratories; and involved in the medical robotics business.
Sysmex Corporation Fundamentals Summary
| SSMX.Y fundamental statistics | |
|---|---|
| Market cap | US$7.53b |
| Earnings (TTM) | US$248.56m |
| Revenue (TTM) | US$3.30b |
Is SSMX.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SSMX.Y income statement (TTM) | |
|---|---|
| Revenue | JP¥524.95b |
| Cost of Revenue | JP¥257.42b |
| Gross Profit | JP¥267.53b |
| Other Expenses | JP¥227.93b |
| Earnings | JP¥39.60b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 65.37 |
| Gross Margin | 50.96% |
| Net Profit Margin | 7.54% |
| Debt/Equity Ratio | 16.8% |
How did SSMX.Y perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/10 14:13 |
| End of Day Share Price | 2026/08/10 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sysmex Corporation is covered by 29 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Masahiro Nakanomyo | Barclays |
| Kei Takeuchi | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |